Literature DB >> 24914093

Proteomic analysis of Class IV lupus nephritis.

Ayodele Alaiya1, Lina Assad2, Dania Alkhafaji3, Zakia Shinwari1, Hadeel Almana2, Mohamed Shoukri4, Lutfi Alkorbi3, Hossamaldin Galal Ibrahim3, Mohamed Said Abdelsalam5, Edward Skolnik6, Chaker Adra7, Mamdouh Albaqumi8.   

Abstract

BACKGROUND: There have been several attempts to standardize the definition and increase reproducibility in classifying lupus nephritis (LN). The last was made by the International Society of Nephrology and Renal Pathology Society in 2003 where the introduction of Class IV subcategories (global and segmental) was introduced.
METHODS: We investigated whether this subdivision is important using a proteomics approach. All patients with renal biopsies along with their clinical outcome of LN were identified and regrouped according to the above 2003 classifications. Fresh-frozen renal biopsies of Class IV LN (global and segmental), antineutrophil cytoplasmic antibody-associated vasculitis and normal tissue were analyzed using two-dimensional gel electrophoresis (2-DE) and mass spectrometry. Differentially expressed proteins were identified and subjected to principal component analysis (PCA), and post hoc analysis for the four sample groups.
RESULTS: PCA of 72 differentially expressed spots separated Class IV global and Class IV segmental from both normal and antineutrophil cytoplasmic antibody-associated vasculitis (ANCA). The 28 identified proteins were used in a post hoc analysis, and showed that IV-global and IV-segmental differ in several protein expression when compared with normal and ANCA. To confirm the proteomic results, a total of 78 patients (50 Class IV-Global and 28 Class IV-Segmental) were re-classified according to 2003 classification. There was no difference in therapy between the groups. The renal survival and patient survivals were similar in both groups.
CONCLUSIONS: There is no strong evidence to support a different outcome between the two subcategories of Class-IV LN and, they should thus be treated the same until further studies indicate otherwise.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  global-segmental; lupus-nephritis; profiles; protein-expression; proteomics; renal-biopsies

Mesh:

Substances:

Year:  2014        PMID: 24914093     DOI: 10.1093/ndt/gfu215

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity.

Authors:  Jessica L Turnier; Hermine I Brunner; Michael Bennett; Ashwaq Aleed; Gaurav Gulati; Wendy D Haffey; Sherry Thornton; Michael Wagner; Prasad Devarajan; David Witte; Kenneth D Greis; Bruce Aronow
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 2.  Diagnostic and prognostic tests in systemic lupus erythematosus.

Authors:  Natalia Vasquez-Canizares; Dawn Wahezi; Chaim Putterman
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-06       Impact factor: 4.098

3.  PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.

Authors:  Sheema Almozyan; Dilek Colak; Fatmah Mansour; Ayodele Alaiya; Olfat Al-Harazi; Amal Qattan; Falah Al-Mohanna; Monther Al-Alwan; Hazem Ghebeh
Journal:  Int J Cancer       Date:  2017-06-30       Impact factor: 7.396

Review 4.  Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.

Authors:  Orthodoxia Nicolaou; Andreas Kousios; Andreas Hadjisavvas; Bernard Lauwerys; Kleitos Sokratous; Kyriacos Kyriacou
Journal:  J Cell Mol Med       Date:  2016-11-23       Impact factor: 5.310

5.  LC‑MS/MS proteomic analysis revealed novel associations of 37 proteins with T2DM and notable upregulation of immunoglobulins.

Authors:  Rabab Asghar Abdulwahab; Ayodele Alaiya; Zakia Shinwari; Abdul Ameer A Allaith; Hayder A Giha
Journal:  Int J Mol Med       Date:  2019-03-08       Impact factor: 4.101

6.  Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage.

Authors:  Shijun He; Xing Liu; Zemin Lin; Yuting Liu; Lei Gu; Hu Zhou; Wei Tang; Jianping Zuo
Journal:  Arthritis Res Ther       Date:  2019-01-29       Impact factor: 5.156

7.  Plasma proteomic analysis of systemic lupus erythematosus patients using liquid chromatography/tandem mass spectrometry with label-free quantification.

Authors:  Rashmi Madda; Shih-Chang Lin; Wei-Hsin Sun; Shir-Ly Huang
Journal:  PeerJ       Date:  2018-05-08       Impact factor: 2.984

8.  Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease.

Authors:  Abhimanyu Amarnani; Joseph R Capri; Puneet Souda; David A Elashoff; Ivan A Lopez; Julian P Whitelegge; Ram R Singh
Journal:  J Proteomics Bioinform       Date:  2019-10-03

9.  Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody.

Authors:  Shuai Wang; Jin Shang; Jing Xiao; Zhanzheng Zhao
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

10.  HMOX1 is partly responsible for phenotypic and functional abnormalities in mesenchymal stem cells/stromal cells from placenta of preeclampsia (PE) patients.

Authors:  Yasser S Basmaeil; Dana Algudiri; Reem Alenzi; Abdullah Al Subayyil; Ayodele Alaiya; Tanvir Khatlani
Journal:  Stem Cell Res Ther       Date:  2020-01-21       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.